Mimedx (MDXG) Other Non-Current Assets (2010 - 2026)
Mimedx's (MDXG) quarterly Other Non-Current Assets came in at $6.9 million in Q1 2026, up 557.06% year-on-year from $1.0 million in Q1 2025, and down 5.33% quarter-over-quarter from $7.3 million in Q4 2025.
Mimedx (MDXG) Other Non-Current Assets (2010 - 2026) Analysis & Trends
Mimedx has disclosed Other Non-Current Assets across 16 years of filings, most recently posting $6.9 million for Q1 2026.
- Other Non-Current Assets for Q1 2026 came in at $6.9 million, up 557.06% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.9 million (up 557.06% YoY), and the FY2025 annual result was $7.3 million, up 8.37% from the prior year.
- Other Non-Current Assets came in at $6.9 million for Q1 2026 at Mimedx, down from $7.3 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $7.3 million in Q4 2025 to a low of $146000.0 in Q2 2023.
- The 5-year median for Other Non-Current Assets is $1.0 million (2025), against an average of $1.9 million.
- Across the five-year window, Other Non-Current Assets tumbled 89.01% in 2023 and soared 3174.15% in 2024, its largest moves.
- Mimedx's Other Non-Current Assets stood at $1.9 million in 2022, then sank by 89.01% to $205000.0 in 2023, then jumped by 3174.15% to $6.7 million in 2024, then climbed by 8.37% to $7.3 million in 2025, then declined by 5.33% to $6.9 million in 2026.
- The last three Other Non-Current Assets figures came in at $6.9 million (Q1 2026), $7.3 million (Q4 2025), and $3.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 12.40 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 60,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.26 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Mimedx | 546.28 Mn | 386.51 Mn | 41.62 Mn | 6.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.89 Mn |
| Dec 31, 2025 | 7.27 Mn |
| Sep 30, 2025 | 2.99 Mn |
| Jun 30, 2025 | 990,000.00 |
| Mar 31, 2025 | 1.05 Mn |
| Dec 31, 2024 | 6.71 Mn |
| Sep 30, 2024 | 1.18 Mn |
| Jun 30, 2024 | 1.24 Mn |
| Mar 31, 2024 | 1.25 Mn |
| Dec 31, 2023 | 205,000.00 |
| Sep 30, 2023 | 149,000.00 |
| Jun 30, 2023 | 146,000.00 |
| Mar 31, 2023 | 147,000.00 |
| Dec 31, 2022 | 1.87 Mn |
| Sep 30, 2022 | 150,000.00 |
| Jun 30, 2022 | 164,000.00 |
| Mar 31, 2022 | 172,000.00 |
| Dec 31, 2021 | 186,000.00 |
| Sep 30, 2021 | 270,000.00 |
| Jun 30, 2021 | 313,000.00 |